Paskas, Svetlana
Mazzon, Emanuela
Basile, Maria Sofia
Cavalli, Eugenio
Al-Abed, Yousef
He, Mingzhu
Rakocevic, Sara
Nicoletti, Ferdinando
Mijatovic, Sanja
Maksimovic-Ivanic, Danijela
Funding for this research was provided by:
Ministarstvo Prosvete, Nauke i Tehnolo?kog Razvoja (grant number 173013)
IRCCS Centro Neurolesi Bonino Pulejo (current research funds 2018)
Article History
Received: 11 December 2018
Accepted: 18 January 2019
First Online: 1 February 2019
Compliance with ethical standards
:
: Svetlana Paskas declares that she has no conflicts of interest. Emanuela Mazzon declares that she has no conflicts of interest. Maria Sofia Basile declares that she has no conflicts of interest. Eugenio Cavalli declares that he has no conflicts of interest. Yousef Al-Abed is a cofounder and shareholder of OncoNOx, which has outlicensed lopinavir-NO to Inflamalps.Mingzhu He declares that she has no conflicts of interest. Sara Rakocevic declares that she has no conflicts of interest. Ferdinando Nicoletti is a cofounder and shareholder of OncoNOx, which has outlicensed lopinavir-NO to Inflamalps. Sanja Mijatovic declares that she has no conflicts of interest. Danijela Maksimovic-Ivanic declares that she has no conflicts of interest.
: This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Animal studies were performed in accordance with local guidelines and approved by the local Institutional Animal Care and Use Committee (IACUC), approval nr. 01–08/17.
: For this type of study, formal consent is not required.